Trial NCT01824836

A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

E1Z11 is a study to determine whether certain genetic information can predict which breast
cancer patients will discontinue treatment with AIs due to the development of musculoskeletal
symptoms (MSS). Women with stage 1-111 breast cancer who are prescribed the aromatase
inhibitor anastrozole as treatment may join.


anastrozole, questionnaire administration, laboratory biomarker analysis, pharmacogenomic studies


Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer


Vered Stearns

See list of participating sites